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Dear sir,
We have read with interest the paper by Nodari et al [1]a n d
the editorial by Dr. Raitt [2] on fish oil fatty acids and
arrhythmic risk in heart failure patients caused by idiopathic
dilated cardiomyopathy. In both publications, the mechanism
by which fish oils may be both pro- and antiarrhythmic are
mentioned but remain un-clarified. The heterogeneous re-
sponse to fish oil in patients with heart disease may be
explained by the arrhythmia mechanism.
The GISSI Trial showed that long-term supplementation
with fish oil reduced cardiovascular mortality following a
myocardial infarction [3]. This could be attributed to a 45%
reduction in sudden death, suggesting a direct antiarrhyth-
mic effect of fish oil in these patients [4]. Subsequently, the
effect of fish oil on arrhythmias was studied in patients with
implanted cardiac defibrillators that suffered from a variety
of cardiac pathologies [5–7]. The results were controversial;
proarrhythmic and antiarrhythmic effects as well as absence
of effects were documented. The recent meta-analysis by
Jenkins and co-workers [8] confirmed heterogeneous out-
comes in fish oil trials and concludes that fish oils need to
be prescribed with caution. The question remains: Why is
the response to fish oil heterogeneous? One possibility is
that the diverse patient populations have different arrhyth-
mogenic substrates (heart failure, acute ischemia, infarcted
myocardium).
Circulating and membrane-bound fish oils shorten the
cardiac action potential duration by modulating several ion
channels (for review see [9]). Shortening of the action
potential, as seen in fish oil fed pigs [10], is proarrhythmic
during acute myocardial ischemia [11]. Blockade of the
cardiac sodium channel by fish oil may slow conduction,
and favor reentrant activation. In contrast, the cardiac action
potential is prolonged during heart failure, leading to
triggered arrhythmias [12]. Action potential or repolariza-
tion time shortening in this setting is antiarrhythmic. In the
patients with idiopathic dilated cardiomyopathy that were
studied by Nodari and coworkers [1], the predominant
arrhythmia mechanism likely is triggered activity. These
triggered arrhythmias are inhibited by fish oil in isolated
myocytes of patients with end-stage heart failure as a result
of cardiac action potential shortening in combination with
lower diastolic calcium levels and a reduced response to β-
adrenergic stimulation [13].
Fish oils also affect heart rate, lipoprotein levels,
inflammatory pathways and hypertrophy and thus also
indirectly may determine whether the heart develops
arrhythmia.
Altogether this leads to a complex situation; fish oil is
antiarrhythmic under conditions of heart failure, and proar-
rhythmic under condition of acute myocardial ischemia.
Patients, especially those with heart disease, may have both
types of arrhythmia mechanisms. This makes the outcome of
dietary supplementation with fish oil difficult to predict.
The paper of Nodari [1] nicely demonstrates that the
effect of fish oil can be best studied in a well defined
patient population. We are of the opinion that fish oil
supplementation can be safely administered in these
patients with idiopathic dilated cardiomyopathy. Whether
or not this is the case for other heart disease patients
depends on the main arrhythmia mechanism.
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